ORTHOWORLD estimates Integra LifeSciences’ (IART) 4Q17 orthopaedic revenue at US $27.42MM, +7.3% from 4Q16, and 2017 revenue of $107.8MM, +8.6% vs. 2016.
Estimated segment sales and growth follow.
4Q17
4Q16
$ Change
% Change
Joint Recon Extremities
$5.8
$5.0
$0.7
14.5%
Trauma
$21.7
$20.5
$1.1
5.6%
Total
$27.4
$25.6
$1.9
7.3%
2017
2016
$ Change
% Change
Joint Recon Extremities
$22.6
$19.5
$3.1
15.9%
Trauma
$85.1
$79.7
$5.4
6.8%
Total
$107.8
$99.2
$8.5
8.6%
Total ankle and shoulder reconstruction portfolios continue to drive IART’s orthopaedic growth, with both growing in double-digits separately and at 25% together, with ankle growing faster than shoulder. The Cadence total ankle launch is experiencing strong momentum both inside and outside of the U.S. Lower extremities, excluding total ankles, were down about -5% in 4Q.
In 2H17, IART implanted the first Cadence ankle as part of a non-randomized, prospective, multi-center postmarket study in the U.S., Canada and Europe. The trial will evaluate 2-year implant survivorship, which will be further evaluated at 5 and 10 years post-op. All patients will receive the Cadence device.
The creation of dedicated sales channels for ortho is underway, and is expected to support stronger performance in 2H18.
ORTHOWORLD estimates Integra LifeSciences’ (IART) 4Q17 orthopaedic revenue at US $27.42MM, +7.3% from 4Q16, and 2017 revenue of $107.8MM, +8.6% vs. 2016.
Estimated segment sales and growth follow.
Q17 Q16 $ Change % Change
Joint...
ORTHOWORLD estimates Integra LifeSciences’ (IART) 4Q17 orthopaedic revenue at US $27.42MM, +7.3% from 4Q16, and 2017 revenue of $107.8MM, +8.6% vs. 2016.
Estimated segment sales and growth follow.
4Q17
4Q16
$ Change
% Change
Joint Recon Extremities
$5.8
$5.0
$0.7
14.5%
Trauma
$21.7
$20.5
$1.1
5.6%
Total
$27.4
$25.6
$1.9
7.3%
2017
2016
$ Change
% Change
Joint Recon Extremities
$22.6
$19.5
$3.1
15.9%
Trauma
$85.1
$79.7
$5.4
6.8%
Total
$107.8
$99.2
$8.5
8.6%
Total ankle and shoulder reconstruction portfolios continue to drive IART’s orthopaedic growth, with both growing in double-digits separately and at 25% together, with ankle growing faster than shoulder. The Cadence total ankle launch is experiencing strong momentum both inside and outside of the U.S. Lower extremities, excluding total ankles, were down about -5% in 4Q.
In 2H17, IART implanted the first Cadence ankle as part of a non-randomized, prospective, multi-center postmarket study in the U.S., Canada and Europe. The trial will evaluate 2-year implant survivorship, which will be further evaluated at 5 and 10 years post-op. All patients will receive the Cadence device.
The creation of dedicated sales channels for ortho is underway, and is expected to support stronger performance in 2H18.
Copy to clipboard 
